{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:28:28Z","timestamp":1790198908462,"version":"4.1.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"4","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.ejps.2013.04.031","type":"journal-article","created":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T06:16:07Z","timestamp":1368080167000},"page":"712-722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Overcoming therapeutic obstacles in inflammatory bowel diseases: A comprehensive review on novel drug delivery strategies"],"prefix":"10.1016","volume":"49","author":[{"given":"F.","family":"Talaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Atyabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Azhdarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dinarvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Saadatzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2013.04.031_b0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijpharm.2005.08.025","article-title":"Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery","volume":"305","author":"Akhgari","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2013.04.031_b0010","first-page":"327","article-title":"Multiparticulate formulation approach to colon specific drug delivery: current perspectives","volume":"9","author":"Ali Asghar","year":"2006","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejps.2013.04.031_b0015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jconrel.2012.11.008","article-title":"Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes","volume":"165","author":"Arranz","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2013.04.031_b0020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0168-3659(93)90188-B","article-title":"An evaluation of pectin as a carrier for drug targeting to the colon","volume":"26","author":"Ashford","year":"1993","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2013.04.031_b0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0378-5173(93)90344-F","article-title":"An in vitro investigation into the suitability of pH-dependent polymers for colonic targeting","volume":"91","author":"Ashford","year":"1993","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2013.04.031_b0550","first-page":"750","article-title":"Polysaccharides as Carrier for Particulate-controlled Delivery Systems","volume":"2","author":"Atyabi","year":"2008","journal-title":"Journal of Biomedical Nanotechnology"},{"key":"10.1016\/j.ejps.2013.04.031_b0035","first-page":"81","article-title":"Preparation of ethylcellulose coated gelatin microspheres as a multiparticulate colonic delivery system for 5-aminosalicilic acid","volume":"3","author":"Atyabi","year":"2004","journal-title":"Iran. J. Pharm. Res."},{"key":"10.1016\/j.ejps.2013.04.031_b0040","first-page":"196","article-title":"Adalimumab: human recombinant immunoglobulin G1 anti-tumor necrosis factor monoclonal antibody","volume":"4","author":"Baker","year":"2004","journal-title":"Rev. Gastroenterol. Disord."},{"key":"10.1016\/j.ejps.2013.04.031_b0045","first-page":"37","article-title":"Animal models of inflammatory bowel disease","volume":"51","author":"Bani\u0107","year":"1997","journal-title":"Acta medica Croatica: casopis Hravatske akademije medicinskih znanosti"},{"key":"10.1016\/j.ejps.2013.04.031_b0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jpeds.2005.05.015","article-title":"The use of lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial","volume":"147","author":"Bausserman","year":"2005","journal-title":"J. Pediatrics"},{"key":"10.1016\/j.ejps.2013.04.031_b0055","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.cgh.2006.03.028","article-title":"A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn\u2019s disease","volume":"4","author":"Braat","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejps.2013.04.031_b0060","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1053\/gast.1997.v113.pm9352848","article-title":"Mesalamine in the maintenance treatment of Crohn\u2019s disease: a meta-analysis adjusted for confounding variables","volume":"113","author":"Camma","year":"1997","journal-title":"Gastroenterology"},{"issue":"Suppl. 3","key":"10.1016\/j.ejps.2013.04.031_b0065","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1016\/S0399-8320(09)73150-1","article-title":"Environmental risk factors in Crohn\u2019s disease and ulcerative colitis: an update","volume":"33","author":"Carbonnel","year":"2009","journal-title":"Gastroent\u00e9rologie clinique et biologique"},{"key":"10.1016\/j.ejps.2013.04.031_b0070","first-page":"33","article-title":"Pharmaceutical approaches to colon targeted drug delivery systems","volume":"6","author":"Chourasia","year":"2003","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejps.2013.04.031_b0075","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijpharm.2006.02.031","article-title":"Preparation and characterization of mucoadhesive polymer-coated nanoparticles","volume":"316","author":"Cui","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2013.04.031_b0080","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.addr.2004.08.011","article-title":"New oral delivery systems for treatment of inflammatory bowel disease","volume":"57","author":"Friend","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2013.04.031_b0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1021\/jm00379a012","article-title":"Drug glycosides: potential prodrugs for colon-specific drug delivery","volume":"28","author":"Friend","year":"1985","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2013.04.031_b0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0168-3659(00)00332-1","article-title":"An in vitro investigation of the suitability of press-coated tablets with hydroxypropylmethylcellulose acetate succinate (HPMCAS) and hydrophobic additives in the outer shell for colon targeting","volume":"70","author":"Fukui","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2013.04.031_b0095","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0378-5173(00)00454-3","article-title":"Preparation of enteric coated timed-release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting","volume":"204","author":"Fukui","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2013.04.031_b0100","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1023\/A:1011921925745","article-title":"Low swelling, crosslinked guar and its potential use as colon-specific drug carrier","volume":"15","author":"Gliko-Kabir","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2013.04.031_b0105","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4253\/wjge.v4.i4.108","article-title":"Colorectal cancer surveillance in patients with inflammatory bowel disease: what is new?","volume":"4","author":"Guagnozzi","year":"2012","journal-title":"World J. Gastrointest. Endosc."},{"key":"10.1016\/j.ejps.2013.04.031_b0110","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3109\/1061186X.2012.734311","article-title":"Design and development of liposomes for colon targeted drug delivery","volume":"21","author":"Gupta","year":"2013","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejps.2013.04.031_b0115","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3390\/md8041305","article-title":"Chitosan based polyelectrolyte complexes as potential carrier materials in drug delivery systems","volume":"8","author":"Hamman","year":"2010","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejps.2013.04.031_b0120","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00001574-200407000-00008","article-title":"Therapy of ulcerative colitis","volume":"20","author":"Hanauer","year":"2004","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.ejps.2013.04.031_b0125","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0378-5173(88)90249-9","article-title":"Gastrointestinal transit of small tablets in patients with ulcerative colitis","volume":"48","author":"Hardy","year":"1988","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2013.04.031_b0130","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0163-7258(92)90057-7","article-title":"Free radicals and other reactive oxygen metabolites in inflammatory bowel disease: cause, consequence or epiphenomenon?","volume":"53","author":"Harris","year":"1992","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2013.04.031_b0135","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.3748\/wjg.v16.i33.4145","article-title":"Effect of probiotics on pro-inflammatory cytokines and NF-\u03bab activation in ulcerative colitis","volume":"16","author":"Hegazy","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejps.2013.04.031_b0140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/10717549709033183","article-title":"Colonic targeting of metronidazole using azo aromatic polymers: development and characterization","volume":"4","author":"Hita","year":"1997","journal-title":"Drug Deliv.: J. Deliv. Target. Ther. Agents"},{"key":"10.1016\/j.ejps.2013.04.031_b0145","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijpharm.2005.10.038","article-title":"A comparative in vitro assessment of the drug release performance of pH-responsive polymers for ileo-colonic delivery","volume":"308","author":"Ibekwe","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2013.04.031_b0150","first-page":"535","article-title":"Formulation and evaluation of compression coated tablets of mesalazine for colon delivery","volume":"2","author":"Jenita","year":"2010","journal-title":"Int. J. PharmTech. Res."},{"key":"10.1016\/j.ejps.2013.04.031_b0155","first-page":"161","article-title":"Inflammatory bowel disease \u2013 drug treatment and its implications","volume":"13","author":"Jones","year":"2006","journal-title":"Hosp. Pharmacist"},{"key":"10.1016\/j.ejps.2013.04.031_b0160","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/11632710-000000000-00000","article-title":"Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients","volume":"72","author":"Jonkers","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2013.04.031_b0165","article-title":"Colon targeted chitosan microsphere compressed matrices for the treatment of ulcerative colitis","volume":"5","author":"Kawadkar","year":"2007","journal-title":"Pharm. Rev."},{"key":"10.1016\/j.ejps.2013.04.031_b0170","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1007\/s11095-005-5376-3","article-title":"Liposomal formulations of inflammatory bowel disease drugs: local versus systemic drug delivery in a rat model","volume":"22","author":"Kesisoglou","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2013.04.031_b0175","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1081\/DDC-100101266","article-title":"A pH-dependent colon-targeted oral drug delivery system using methacrylic acid copolymers. II. Manipulation of drug release using Eudragit\u00ae L100 and Eudragit S100 combinations","volume":"26","author":"Khan","year":"2000","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2013.04.031_b0180","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s002280000163","article-title":"The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease","volume":"56","author":"Klotz","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2013.04.031_b0185","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0169-409X(91)90048-H","article-title":"Peroral administration of nanoparticles","volume":"7","author":"Kreuter","year":"1991","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2013.04.031_b0190","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2010.10.002","article-title":"Oral TNF-\u03b1 gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease","volume":"150","author":"Kriegel","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2013.04.031_b0195","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0928-0987(03)00139-8","article-title":"In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets","volume":"19","author":"Krishnaiah","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2013.04.031_b0200","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gut.2003.037747","article-title":"Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine","volume":"53","author":"Kruis","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2013.04.031_b0205","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1046\/j.1365-2036.1997.00225.x","article-title":"Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis","volume":"11","author":"Kruis","year":"1997","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2013.04.031_b0210","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3748\/wjg.v13.i8.1149","article-title":"Practical guidelines for the treatment of inflammatory bowel disease","volume":"13","author":"Kuhbacher","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejps.2013.04.031_b0215","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1023\/A:1011032328064","article-title":"Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa","volume":"18","author":"Lamprecht","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2013.04.031_b0220","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0168-3659(01)00230-9","article-title":"Design of rolipram-loaded nanoparticles: comparison of two preparation methods","volume":"71","author":"Lamprecht","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2013.04.031_b0225","first-page":"775","article-title":"Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease","volume":"299","author":"Lamprecht","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2013.04.031_b0230","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0168-3659(03)00195-0","article-title":"Microsphere design for the colonic delivery of 5-fluorouracil","volume":"90","author":"Lamprecht","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2013.04.031_b0235","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2005.02.011","article-title":"A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles","volume":"104","author":"Lamprecht","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2013.04.031_b0240","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1124\/jpet.105.088146","article-title":"Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats","volume":"315","author":"Lamprecht","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2013.04.031_b0245","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejpb.2004.01.003","article-title":"Design of pH-sensitive microspheres for the colonic delivery of the immunosuppressive drug tacrolimus","volume":"58","author":"Lamprecht","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2013.04.031_b0250","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0167-7799(98)01220-7","article-title":"Novel applications of liposomes","volume":"16","author":"Lasic","year":"1998","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ejps.2013.04.031_b0255","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1081\/DDC-100102305","article-title":"Basic coating polymers for the colon-specific drag delivery in inflammatory bowel disease","volume":"26","author":"Leopold","year":"2000","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2013.04.031_b0260","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/jcp.56.12.885","article-title":"Basement membrane components","volume":"56","author":"Li","year":"2003","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.ejps.2013.04.031_b0265","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00054725-200105000-00002","article-title":"Is infliximab effective for induction of remission in patients with ulcerative colitis?","volume":"7","author":"Lichtenstein","year":"2001","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejps.2013.04.031_b0270","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1023\/A:1015887318767","article-title":"Calcium alginate beads as core carriers of 5-aminosalicylic acid","volume":"9","author":"Lin","year":"1992","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2013.04.031_b0275","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa033402","article-title":"Anti-interleukin-12 antibody for active Crohn\u2019s disease","volume":"351","author":"Mannon","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2013.04.031_b0280","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0928-0987(97)10007-0","article-title":"Binding and uptake of biodegradable poly-dl-lactide micro- and nanoparticles in intestinal epithelia","volume":"6","author":"McClean","year":"1998","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2013.04.031_b0285","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijpharm.2006.01.032","article-title":"Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery","volume":"316","author":"Meissner","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2013.04.031_b0290","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0168-3659(95)00112-3","article-title":"Amylose as a coating for drug delivery to the colon: preparation and in vitro evaluation using 5-aminosalicylic acid pellets","volume":"38","author":"Milojevic","year":"1996","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2013.04.031_b0295","first-page":"59","article-title":"Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease","volume":"38","author":"Nakase","year":"2003","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.ejps.2013.04.031_b0300","first-page":"15","article-title":"Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy","volume":"292","author":"Nakase","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2013.04.031_b0305","first-page":"1122","article-title":"An oral drug delivery system targeting immune-regulating cells ameliorates mucosal injury in trinitrobenzene sulfonic acid-induced colitis","volume":"297","author":"Nakase","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2013.04.031_b0310","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.trsl.2011.09.001","article-title":"Inflammatory bowel disease: role of diet, microbiota, life style","volume":"160","author":"Neuman","year":"2012","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejps.2013.04.031_b0315","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/gut.52.9.1286","article-title":"Interferon \u03b2-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study","volume":"52","author":"Nikolaus","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2013.04.031_b0320","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/BF03326413","article-title":"Intestinal drug delivery systems with biodegradable microspheres targeting mucosal immune-regulating cells for chronic inflammatory colitis","volume":"37","author":"Okazaki","year":"2002","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.ejps.2013.04.031_b0325","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1572-0241.2005.40647.x","article-title":"Safety and efficacy of adalimumab (D2E7) in Crohn\u2019s disease patients with an attenuated response to infliximab","volume":"100","author":"Papadakis","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejps.2013.04.031_b0330","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.gtc.2007.03.001","article-title":"Prebiotics, probiotics, and dietary fiber in gastrointestinal disease","volume":"36","author":"Park","year":"2007","journal-title":"Gastroenterol. Clin. North Am."},{"key":"10.1016\/j.ejps.2013.04.031_b0335","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jconrel.2007.08.008","article-title":"5-Amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease","volume":"123","author":"Pertuit","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2013.04.031_b0340","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.3748\/wjg.v18.i23.2895","article-title":"Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases","volume":"18","author":"Pichai","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejps.2013.04.031_b0345","first-page":"PI13","article-title":"Meta-analysis technique confirms the effectiveness of anti-TNF-\u03b1 in the management of active ulcerative colitis when administered in combination with corticosteroids","volume":"13","author":"Rahimi","year":"2007","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.ejps.2013.04.031_b0350","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1007\/s10620-007-0171-0","article-title":"A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn\u2019s disease","volume":"53","author":"Rahimi","year":"2008","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejps.2013.04.031_b0355","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijmm.2009.08.004","article-title":"Inflammatory bowel disease, gut bacteria and probiotic therapy","volume":"300","author":"Reiff","year":"2010","journal-title":"Int. J. Med. Microbiol."},{"key":"10.1016\/j.ejps.2013.04.031_b0360","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(98)06343-0","article-title":"Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial","volume":"354","author":"Rembacken","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2013.04.031_b0365","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0168-3659(98)00029-7","article-title":"Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region","volume":"55","author":"Rodr\u00edguez","year":"1998","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2013.04.031_b0370","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/bdd.2510110602","article-title":"Microbially controlled drug delivery to the colon","volume":"11","author":"Rubinstein","year":"1990","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2013.04.031_b0375","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ddtec.2005.05.021","article-title":"Colonic drug delivery","volume":"2","author":"Rubinstein","year":"2005","journal-title":"Drug Discov. Today: Technol."},{"key":"10.1016\/j.ejps.2013.04.031_b0380","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2013.04.031_b0385","first-page":"S3","article-title":"An historical overview of the treatment of Crohn\u2019s disease: why do we need biological therapies?","volume":"4","author":"Rutgeerts","year":"2004","journal-title":"Rev. Gastroenterol. Disord."},{"key":"10.1016\/j.ejps.2013.04.031_b0390","article-title":"Biochemical and pathological evidences on the benefit of a new biodegradable nanoparticles of probiotic extract in murine colitis","author":"Saadatzadeh","year":"2011","journal-title":"Fundamental and Clinical Pharmacology"},{"key":"10.1016\/j.ejps.2013.04.031_b0395","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn\u2019s disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2013.04.031_b0400","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/j.1572-0241.2004.40462.x","article-title":"An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn\u2019s disease","volume":"99","author":"Sandborn","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejps.2013.04.031_b0405","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0168-3659(01)00291-7","article-title":"In vitro and in vivo evaluation of an oral system for time and\/or site-specific drug delivery","volume":"73","author":"Sangalli","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2013.04.031_b0410","first-page":"451","article-title":"Metabolism of foreign compounds by gastrointestinal microorganisms","volume":"25","author":"Scheline","year":"1973","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejps.2013.04.031_b0415","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn\u2019s disease","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejps.2013.04.031_b0420","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/gut.30.4.486","article-title":"Dendritic cells and scavenger macrophages in chronic inflammatory bowel disease","volume":"30","author":"Seldenrijk","year":"1989","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2013.04.031_b0425","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.addr.2003.11.003","article-title":"Probiotics in inflammatory bowel disease \u2013 therapeutic rationale and role","volume":"56","author":"Shanahan","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2013.04.031_b0430","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/01.mcg.0000140188.88275.65","article-title":"Current therapeutic recommendations: infliximab for ulcerative colitis","volume":"38","author":"Shen","year":"2004","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.ejps.2013.04.031_b0435","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ijpharm.2003.12.015","article-title":"Amylose formulations for drug delivery to the colon: a comparison of two fermentation models to assess colonic targeting performance in vitro","volume":"273","author":"Siew","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2013.04.031_b0440","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1023\/A:1011033121528","article-title":"Colonic drug delivery: prodrug approach","volume":"18","author":"Sinha","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2013.04.031_b0445","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0378-5173(01)00720-7","article-title":"Polysaccharides in colon-specific drug delivery","volume":"224","author":"Sinha","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2013.04.031_b0450","first-page":"41","article-title":"Coating polymers for colon specific drug delivery: a comparative in vitro evaluation","volume":"53","author":"Sinha","year":"2003","journal-title":"Acta Pharm."},{"key":"10.1016\/j.ejps.2013.04.031_b0455","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0928-0987(02)00221-X","article-title":"Microbially triggered drug delivery to the colon","volume":"18","author":"Sinha","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2013.04.031_b0460","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000544","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","author":"Sutherland","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejps.2013.04.031_b0465","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0264-410X(96)00149-1","article-title":"Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres","volume":"14","author":"Tabata","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.ejps.2013.04.031_b0470","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/10611869708995842","article-title":"Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs","volume":"4","author":"Takaya","year":"1997","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejps.2013.04.031_b0475","first-page":"1","article-title":"Aberrations in proteostasis orchestrate: the genotypic and phenotypic changes in aging","volume":"1","author":"Talaei","year":"2012","journal-title":"Am. J. Mol. Cell. Biol."},{"key":"10.1016\/j.ejps.2013.04.031_b0480","first-page":"1963","article-title":"Thiolated chitosan nanoparticles as a delivery system for antisense therapy: evaluation against EGFR in T47D breast cancer cells","volume":"6","author":"Talaei","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejps.2013.04.031_b0485","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1021\/mp9000926","article-title":"Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa","volume":"6","author":"Tirosh","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2013.04.031_b0490","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2013.04.031_b0495","first-page":"443","article-title":"Medical treatment of inflammatory bowel diseases","volume":"21","author":"Van Assche","year":"2005","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"2","key":"10.1016\/j.ejps.2013.04.031_b0555","first-page":"107","article-title":"Development of novel budesonide pellets based on CODESTM technology: in vitro\/in vivo evaluation in induced colitis in rats","volume":"19","author":"Varshosaz","year":"2011","journal-title":"DARU, Journal of Pharmaceutical Sciences."},{"key":"10.1016\/j.ejps.2013.04.031_b0505","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijfoodmicro.2006.10.020","article-title":"Mucosal immunomodulation by the non-bacterial fraction of milk fermented by Lactobacillus helveticus R389","volume":"115","author":"Vinderola","year":"2007","journal-title":"Int. J. Food Microbiol."},{"key":"10.1016\/j.ejps.2013.04.031_b0510","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0378-5173(92)90245-W","article-title":"The transit rate of different-sized model dosage forms through the human colon and the effects of a lactulose-induced catharis","volume":"87","author":"Watts","year":"1992","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2013.04.031_b0515","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3109\/03639049709148695","article-title":"Colonic drug delivery","volume":"23","author":"Watts","year":"1997","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2013.04.031_b0520","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nmat2859","article-title":"Orally delivered thioketal nanoparticles loaded with TNF-\u03b1\u2013siRNA target inflammation and inhibit gene expression in the intestines","volume":"9","author":"Wilson","year":"2010","journal-title":"Nat. Mater."},{"key":"10.1016\/j.ejps.2013.04.031_b0525","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0168-3659(97)01633-7","article-title":"USP dissolution apparatus III (reciprocating cylinder) for screening of guar-based colonic delivery formulations","volume":"47","author":"Wong","year":"1997","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2013.04.031_b0530","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1517\/17425247.2012.730517","article-title":"Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease","volume":"9","author":"Xiao","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejps.2013.04.031_b0535","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijpharm.2008.12.007","article-title":"Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor","volume":"371","author":"Yang","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2013.04.031_b0540","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/jps.20802","article-title":"Different HPMC viscosity grades as coating agents for an oral time and\/or site-controlled delivery system: an investigation into the mechanisms governing drug release","volume":"96","author":"Zema","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2013.04.031_b0545","first-page":"411","article-title":"Probiotics and remission of ulcerative colitis: a systematic review","volume":"65","author":"Zigra","year":"2007","journal-title":"Neth. J. Med."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098713001747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098713001747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T15:41:59Z","timestamp":1563032519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098713001747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":109,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0928098713001747"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2013.04.031","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming therapeutic obstacles in inflammatory bowel diseases: A comprehensive review on novel drug delivery strategies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2013.04.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}